WEBULL

Can IDEXX Laboratories' (IDXX) Recurring Revenue Model Sustain Its Competitive Edge in Evolving Vet Markets?

Simply Wall St · 07/30/2025 10:15
  • IDEXX Laboratories recently drew positive attention for its approach to integrating more deeply with veterinary practices and for its strong, recurring revenue streams, highlighted in news coverage earlier this week.
  • This focus on resilience and innovation, as pandemic-driven demand normalizes, is setting the company apart for those seeking dependable, long-term industry opportunities.
  • We’ll examine how IDEXX’s "surround the customer" strategy and recurring business model shape its evolving investment narrative.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

IDEXX Laboratories Investment Narrative Recap

To invest in IDEXX Laboratories, you need to believe in the enduring growth of animal health diagnostics, the company's leading position, and its ability to generate stable, recurring revenues from veterinary practice integration. The recent spotlight on its "surround the customer" strategy underscores IDEXX’s focus on long-term relationships, but doesn’t fundamentally change the most important short-term catalyst, growth in clinical diagnostics utilization, or the biggest current risk, which remains softness in U.S. clinical visits impacting earnings momentum.

One recent announcement aligned with this theme is the launch of the Catalyst® Cortisol Test, which expands IDEXX’s menu of in-practice diagnostics. This addition supports the company’s recurring revenue strategy and could help offset the impact from softer visit trends by giving veterinarians more reasons to use IDEXX platforms for routine screening and disease monitoring.

But while product innovation continues, investors should also be aware of key challenges, shifting trends in clinical visit volume, in particular, may...

Read the full narrative on IDEXX Laboratories (it's free!)

IDEXX Laboratories' narrative projects $4.9 billion revenue and $1.2 billion earnings by 2028. This requires 7.9% yearly revenue growth and a $305 million earnings increase from $895.0 million.

Uncover how IDEXX Laboratories' forecasts yield a $519.99 fair value, a 9% downside to its current price.

Exploring Other Perspectives

IDXX Community Fair Values as at Jul 2025
IDXX Community Fair Values as at Jul 2025

Three Simply Wall St Community fair value estimates for IDEXX range from US$406.38 to US$519.99, reflecting a broad span of independent forecasts. Focus on recurring revenue and customer integration remains central, but ongoing changes in veterinary clinical activity could affect performance beyond pure valuation signals.

Explore 3 other fair value estimates on IDEXX Laboratories - why the stock might be worth as much as $519.99!

Build Your Own IDEXX Laboratories Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.